Loading…
Based on limited metadata, SpiceTac received an FDA Warning Letter on May 19, 2020, regarding drug products under the agency's regulatory authority. Without access to the full letter text or detailed subject line, the specific nature of the compliance violations cannot be determined from the available information. The warning indicates that the company's drug manufacturing, marketing, or quality practices did not meet FDA requirements, though the particular deficiencies would require review of the complete correspondence to identify.